Browse the evidence

The Healthy Weight for Living (HWL) intervention resulted in a mean 6-month weight change of −8.8% for HWL and −8.0% for HWL + meal replacements (MR), both significantly better than controls (p < 0.001).

Implementing the HWL intervention can lead to significant weight loss in workplace settings.

Clinically meaningful weight loss (≥5%) was maintained at 18 months in both intervention groups.

The HWL intervention can lead to sustained weight loss over an extended period.

The HWL intervention can be delivered via videoconference and is effective with or without meal replacements.

Practitioners can implement the HWL intervention remotely, making it accessible for various workplace settings.

63.4% of survivors of adolescent and young adult cancer had ≥5% weight reduction after anti-obesity medication initiation.

Practitioners may consider AOMs as a viable option for weight management in this population.

The proportion of survivors with severe obesity decreased from 60% to 35% after anti-obesity medication initiation.

AOMs may effectively reduce severe obesity in this demographic.

Anti-obesity medications are effective for weight reduction in survivors of adolescent and young adult cancer.

AOMs can be considered a treatment option for weight management in AYA cancer survivors.

Semaglutide add-on to metformin significantly decreases the Visceral Adiposity Index (VAI) in type 2 diabetic patients, with the greatest reduction in the obesity group (-0.70).

Incorporating semaglutide with metformin may enhance fat loss in patients with type 2 diabetes, especially those with obesity.

Weight loss is associated with improvement in cardiovascular risk, menstrual cycles, ovulation, and pregnancy rate in women with obesity and PCOS.

Weight loss should be prioritized in treatment plans for women with obesity and PCOS to improve health outcomes.

Lifestyle modifications are often the first-line intervention for improving hormonal imbalances and menstrual cycles in women with PCOS.

Clinicians should consider lifestyle modifications as a primary strategy in managing PCOS.

Tirzepatide 10 mg was associated with a reduction in predicted 10-year risk of type 2 diabetes from 5.3% to 1.2%.

Practitioners may consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.

Tirzepatide 15 mg was associated with a reduction in predicted 10-year risk of type 2 diabetes from 4.9% to 1.0%.

Practitioners may consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.

Two-thirds of respondents reported reduced appetite, food cravings, or body weight.

Practitioners can expect that a significant portion of patients may experience appetite reduction and weight loss with Ozempic.

Tirzepatide yields greater weight loss and broad metabolic benefits.

Clinicians may prefer tirzepatide for patients focused on weight loss and metabolic improvements.

Exogenous β-hydroxybutyrate (BHB) supplementation significantly reduced fat mass by 2 kg and improved body fat percentage in overweight and obese adults.

Practitioners may consider BHB supplementation as a strategy to enhance fat loss in overweight and obese clients.

Lean mass was largely preserved with no declines in resting metabolic rate (RMR) in the BHB group.

BHB supplementation may help maintain lean mass during caloric restriction.

Patients treated with GLP-1RAs achieved a mean absolute weight loss of 7.33 kg compared to baseline.

GLP-1RAs can be effective for weight loss in IBD patients.

GLP-1 receptor agonist type drugs can help patients achieve considerable weight loss.

Practitioners can consider GLP-1 RAs as a treatment option for weight loss in obese patients.

Semaglutide (Wegovy) has demonstrated unprecedented efficacy in weight reduction, glycaemic control, and cardiovascular protection.

Semaglutide may be a highly effective treatment option for obesity and type 2 diabetes.

Achieving ≥ 5% total weight loss (TWL) is associated with a higher risk ratio (RR) of type 2 diabetes remission (RR = 7.88).

Practitioners should encourage patients to aim for at least 5% weight loss to improve diabetes remission rates.

Achieving ≥ 5% TWL is associated with a higher RR of hypertension remission (RR = 2.23).

Encouraging weight loss of at least 5% may help patients achieve better blood pressure control.

Achieving ≥ 5% TWL leads to significant mean differences in metabolic risk factors including HbA1c, fasting plasma glucose, and blood pressure.

Weight loss of at least 5% can lead to significant improvements in key metabolic health indicators.

Subcutaneous semaglutide 0.5 mg and subcutaneous liraglutide 3 mg are effective treatments for reducing weight among people with obesity in a real-world scenario after 3 months.

Both semaglutide and liraglutide can be considered effective options for weight management in clinical practice.

Weight reduction starting at 5% body weight confers metabolic protection, such as improved hypertension and dysglycemia.

Encouraging patients to achieve at least a 5% weight loss can improve their metabolic health.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide potent weight reduction among persons with overweight/obesity and show cardiovascular benefits.

GLP-1 RAs may be considered as a therapeutic option for weight management in patients with HIV and obesity.